IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

HBM Holdings Limited / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/harbour-biomed-holdings-limited" target="_blank" data-smartkarma-citation="entities:29717:1" rel="noopener">Harbour Biomed (HMD HK)</a> is a biopharmaceutical company with a focus on discovering, developing and commercialising differentiated antibody therapeutics in immunology and oncology disease areas. Harbour is backed by Legend Capital, GIC, CDH Investments, <a href="https://www.smartkarma.com/entities/sk-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:393:1" rel="noopener">SK Holdings (034730 KS)</a>, OrbiMed, Octagon Capital and Sage Partners. The Series C round in July 2020 raised $102.8 million at a post-money valuation of $780 million. <div class="content-highlight">Harbour is seeking to raise $300 million through a Hong Kong IPO, according to press reports. Harbour’s three antibody platforms (HCAb Platform, HBICE Platform and H2L2 Platform) are a key source of differentiation. Overall, we believe that Harbour’s clinical assets are attractive. </div>

Harbour Biomed (HMD HK) is a biopharmaceutical company with a focus on discovering, developing and commercialising differentiated antibody therapeutics in immunology and oncology disease areas. Harbour is backed by Legend Capital, GIC, CDH Investments, SK Holdings (034730 KS), OrbiMed, Octagon Capital and Sage Partners. The Series C round in July 2020 raised $102.8 million at a post-money valuation of $780 million. Harbour is seeking to raise $300 million through a Hong Kong IPO, according to press reports. Harbour’s three antibody platforms (HCAb Platform, HBICE Platform and H2L2 Platform) are a key source of differentiation. Overall, we believe that Harbour’s clinical assets are attractive. 

HBM Holdings (Harbour Biomed) IPO Initiation: Making Resistance Futile

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

Throughout the year 2020, the COVID-19 had certain negative impact on the economy. The pharmaceutical industry has the attributes of relatively rigid demand and countercyclical, and some medical products and services were benefited from the epidemic. Therefore, in 2020/1H, the pharmaceutical industry outperformed the market significantly. As the epidemic in China has been effectively under control and the resumption of work and production has been comprehensively promoted, domestic investment hotspots have been frequently switched, and the pharmaceutical sector has undergone periodic adjustments. Besides, in 2020/2H, the advance of new volume-based purchasing policy in the field of drugs and high-value medical consumables also negatively impact the performance of healthcare sector. However, the development and potential of the China healthcare industry is still very promising, and there will be good investment opportunities in the future.

Throughout the year 2020, the COVID-19 had certain negative impact on the economy. The pharmaceutical industry has the attributes of relatively rigid demand and countercyclical, and some medical products and services were benefited from the epidemic. Therefore, in 2020/1H, the pharmaceutical industry outperformed the market significantly. As the epidemic in China has been effectively under control and the resumption of work and production has been comprehensively promoted, domestic investment hotspots have been frequently switched, and the pharmaceutical sector has undergone periodic adjustments. Besides, in 2020/2H, the advance of new volume-based purchasing policy in the field of drugs and high-value medical consumables also negatively impact the performance of healthcare sector. However, the development and potential of the China healthcare industry is still very promising, and there will be good investment opportunities in the future. 

2021 High Conviction - Investment Opportunities in China Healthcare Industry

1. Industry viewpoints: <ul>
<li>A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.</li>
<li>Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.</li>
<li>Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.</li>
</ul>2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints: 
A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.
Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.
Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.
2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Equity Bottom-Up

Jiangsu Hengrui Medicine / Equity Bottom-Up

<a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a> recently released the third quarter report. The Q1-Q3 accumulated revenue was RMB19.413 billion, with a YoY growth rate of 14.57%. Q1-Q3 single quarter growth rate was 11%, 14% and 17% respectively. Net income attributed to shareholders in the first three quarters was RMB4.259 billion, up 14.02% YoY. Q3 single quarter net income attributed to shareholders reached RMB1.597 billion, up 21% YoY. Q1-Q3 and Q3’s net income after deducting non-recurring gains and losses were RMB4.141 billion and RMB1.579 billion, up 17% and 27% YoY respectively. Net operating cash flow increased 53% YoY in the first three quarters. If excluding the impact of equity incentive plan, the performance in third quarter report will be even better.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/167/757/original/image_57569591631603763698845.png?1603763700" class="editor-image img-responsive" data-smartkarma-image-id="167757"></figure>Source: WIND, Hengrui’s financial report

Jiangsu Hengrui Medicine (600276 CH) recently released the third quarter report. The Q1-Q3 accumulated revenue was RMB19.413 billion, with a YoY growth rate of 14.57%. Q1-Q3 single quarter growth rate was 11%, 14% and 17% respectively. Net income attributed to shareholders in the first three quarters was RMB4.259 billion, up 14.02% YoY. Q3 single quarter net income attributed to shareholders reached RMB1.597 billion, up 21% YoY. Q1-Q3 and Q3’s net income after deducting non-recurring gains and losses were RMB4.141 billion and RMB1.579 billion, up 17% and 27% YoY respectively. Net operating cash flow increased 53% YoY in the first three quarters. If excluding the impact of equity incentive plan, the performance in third quarter report will be even better.Source: WIND, Hengrui’s financial report

Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline

1. Industry viewpoints: <ul>
<li>China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.</li>
<li>
With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 
</li>
<li>In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China</li>
</ul>2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

1. Industry viewpoints: 
China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.

With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 

In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China
2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

China

Jiangsu Hengrui Medicine Co., Ltd. develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company's products include anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and other related products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Hengrui Medicine (600276 CH)

HBM Holdings (Harbour Biomed) IPO Initiation: Making Resistance Futile

Harbour is seeking to raise $300 million through a Hong Kong IPO. Harbour’s three antibody platforms are a key source of differentiation. Overall,...

Arun George

2021 High Conviction - Investment Opportunities in China Healthcare Industry

This article reviewed the performance of China healthcare industry in 2020 and analyzed good investment opportunities (innovative drugs, CRO/CDMO,...

Xinyao (Criss) Wang

China Healthcare Weekly (Nov.6)

This article summarized the new healthcare policy released in China, major industry viewpoints, company news and capital markets review for the...

Xinyao (Criss) Wang